-
- Maria Karasarides
- 1Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey.
-
- Alexandria P. Cogdill
- 2Immunai, New York, New York.
-
- Paul B. Robbins
- 4Instil Bio, Dallas, Texas.
-
- Michaela Bowden
- 5Translational Medicine, Bristol Myers Squibb, Cambridge, Massachusetts.
-
- Elizabeth M. Burton
- 6Department of Surgical Oncology, The University of Texas MD Anderson, Houston, Texas.
-
- Lisa H. Butterfield
- 7Parker Institute for Cancer Immunotherapy, San Francisco, California.
-
- Alessandra Cesano
- 9ESSA Pharma Inc., South San Francisco, California.
-
- Christian Hammer
- 10Department of Cancer Immunology, Genentech, South San Francisco, California.
-
- Cara L. Haymaker
- 12Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
-
- Christine E. Horak
- 13Global Drug Development, Bristol Myers Squibb, Lawrenceville, New Jersey.
-
- Heather M. McGee
- 14Department of Radiation Oncology, City of Hope National Medical Center and Department of Immuno-Oncology, Beckmann Research Institute, City of Hope, Duarte, California.
-
- Anne Monette
- 15Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
-
- Nils-Petter Rudqvist
- 16University of Texas MD Anderson Cancer Center, Houston, Texas.
-
- Christine N. Spencer
- 17Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California.
-
- Randy F. Sweis
- 19Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
-
- Benjamin G. Vincent
- 22Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
-
- Erik Wennerberg
- 23The Institute of Cancer Research, London, UK.
-
- Jianda Yuan
- 24Translational Oncology, Early Oncology Development Department, Merck Research Laboratories, Rahway, New Jersey.
-
- Roberta Zappasodi
- 25Weill Cornell Medicine, New York, New York.
-
- Vanessa M. Hubbard Lucey
- 1Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey.
-
- Daniel K. Wells
- 2Immunai, New York, New York.
-
- Theresa LaVallee
- 7Parker Institute for Cancer Immunotherapy, San Francisco, California.
書誌事項
- 公開日
- 2022-03-14
- 権利情報
-
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1158/2326-6066.cir-20-0586
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:sec> <jats:title/> <jats:p>Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. Treatment resistance to ICIs remains a major challenge and defines the biggest unmet medical need in oncology worldwide. In a collaborative workshop, thought leaders from academic, biopharma, and nonprofit sectors convened to outline a resistance framework to support and guide future immune-resistance research. Here, we explore the initial part of our effort by collating seminal discoveries through the lens of known biological processes. We highlight eight biological processes and refer to them as immune resistance nodes. We examine the seminal discoveries that define each immune resistance node and pose critical questions, which, if answered, would greatly expand our notion of immune resistance. Ultimately, the expansion and application of this work calls for the integration of multiomic high-dimensional analyses from patient-level data to produce a map of resistance phenotypes that can be utilized to guide effective drug development and improved patient outcomes.</jats:p> </jats:sec>
収録刊行物
-
- Cancer Immunology Research
-
Cancer Immunology Research 10 (4), 372-383, 2022-03-14
American Association for Cancer Research (AACR)
